Login
$BMRA
$1.32 -$0.04 (2.94%) Live

Company Executives

Officer Age In this role Joined 2026 pay Source
Zackary Irani Also a director
Chief Executive Officer and Director
60 Since 1997
29 years
Not stated $285,450
Allen Barbieri Also a director
Executive Vice-Chairperson of the Board and Corporate Secretary
68 Since 2020
6 years
Not stated $165,400
Xiaoxuan (“Jenny”) Qu
See Remarks
Title from the Form 3 dated Aug 27, 2026
33 Not stated 2023 Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
5
serving now
Independent
3 of 3
stated in the proxy; 2 not stated
Average tenure
14.5 years
from year joined
Director Age On board Independent Committees Pay Source
Zackary Irani
60 1997
29 years
Not stated None stated Paid as CEO
Allen Barbieri
68 1999
27 years
Not stated None stated Not stated
Eric Bing Chin
46 2025
1 year
Independent
Audit · Chair Compensation Nominating and Corporate Governance
Not stated
Gary Huff
60 2025
1 year
Independent
Nominating and Corporate Governance · Chair Audit Compensation
Not stated
David Moatazedi Leaving at the meeting
Not stated Not stated Independent None stated Not stated
Nominated to join at the meeting
Not on the board yet; they join only if elected.

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

7 disclosed in the proxy filed Oct 16, 2026
Zackary S. Irani
Chief Executive Officer and a director
$500,000
2026

Sale of the Company's entire minority investment in Diagnosis S.A. (78,750 shares) to purchasers including Mr. Irani.

$500,000

Secured promissory term note issued by the Company to Mr. Irani bearing 8% interest and maturing May 29, 2027, secured by the Diagnosis S.A. shares.

With the Company Open in proxy
Zackary S. Irani
Director and Chief Executive Officer
$ 50,000

Purchased 31,250 shares in the August 2026 Private Placement at $1.60 per share.

With the Company Open in proxy
Allen Barbieri
Director, Executive Vice-Chairperson of the Board and Corporate Secretary
$ 32,000

Purchased 20,000 shares in the August 2026 Private Placement at $1.60 per share.

With the Company Open in proxy
Eric B. Chin
Director
$ 10,000

Purchased 6,250 shares in the August 2026 Private Placement at $1.60 per share.

With the Company Open in proxy
Gary M. Huff
Director
$ 50,000

Purchased 31,250 shares in the August 2026 Private Placement at $1.60 per share.

With the Company Open in proxy
David Moatazedi
Director
$ 16,000

Purchased 10,000 shares in the August 2026 Private Placement at $1.60 per share.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support